Lung adenocarcinomas and lung cancer cell lines show association of MMP-1 expression with STAT3 activation

Translational Oncology

Volumn 8, Issue 2, 2015, Pages 97-105

  Schütz, Alexander ^a,f   Röser, Katrin ^b,g   Klitzsch, Jana ^a   Lieder, Franziska ^b,h   Aberger, Fritz ^c   Gruber, Wolfgang ^c   Mueller, Kristina M ^d   Pupyshev, Alexander ^e   Moriggl, Richard ^d   Friedrich, Karlheinz ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY OF SALZBURG   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e NOVOSIBIRSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^f Inst F Pathologie am Elsapark   (Germany)

^g Alere Technologies GmbH   (Germany)

^h Novartis Consumer Health   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; STAT3 PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; LUNG ADENOCARCINOMA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCORING SYSTEM; UPREGULATION; WESTERN BLOTTING;

EID: 84929855338     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2015.02.002     Document Type: Article

References (44)

1. Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA, Anderson RN, and Thun MJ (2003). Long-term trends in cancer mortality in the United States, 1930–1998. Cancer 97(12 Suppl.), 3133–3175.
2. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, and Dmitrovsky E (1993). Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53(10 Suppl.), 2379–2385.
3. Mazurenko NN, Kogan EA, Zborovskaya IB, and Kisseljov FL (1992). Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer 28, 372–377.
4. Bihl M, Tamm M, Nauck M, Wieland H, Perruchoud AP, and Roth M (1998). Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6. Am J Respir Cell Mol Biol 19, 606–612.
5. Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, and Hallahan DE (2004). Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 91, 5735–5740.
6. Levy DE and Lee CK (2012). What does Stat3 do? J Clin Invest 109, 1143–1148.
7. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, and Darnell Jr JE (1999). Stat3 as an oncogene. Cell 98, 295–303.
8. Bromberg J (2002). Stat proteins and oncogenesis. J Clin Invest 109, 1139–1142.
9. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, and Zatloukal K, et al (2005). Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7, 545–555.
10. Song L, Turkson J, Karras JG, Jove R, and Haura EB (2003). Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22, 4150–4165.
11. Seki Y, Suzuki N, Imaizumi M, Iwamoto T, Usami N, Ueda Y, and Hamaguchi M (2004). STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. Int JOncol 24, 931–934.
12. Martín F, Santolaria F, Batista N, Milena A, González-Reimers E, Brito MJ, and Oramas J (1999). Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11, 80–86.
13. Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, and Dubinett S (2005). Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 11, 7674–7682.
14. Yeh HH, Lai WW, and Chen HH (2006). Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 25, 4300–4309.
15. Alvarez JV, Greulich H, Sellers WR, Meyerson M, and Frank DA (2006). Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 66, 3162–3168.
16. Haura EB, Zheng Z, Song L, Cantor A, and Bepler G (2005). Activated epidermal growth factor receptor–Stat-3 signaling promotes tumor survival in vivo in non–small cell lung cancer. Clin Cancer Res 11, 8288–8294.
17. Damstrup L, Rude Voldborg B, Spang-Thomsen M, Brünner N, and Skovgaard Poulsen H (1998). In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer 78, 631–640.
18. Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng KS, and Huang CY (2005). IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 289, L446–L453.
19. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, and Bromberg JF (2004). Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 101, 10602–10607.
20. Xie TX, Wei D, Liu M, Gao AC, Ali-Osman F, Sawaya R, and Huang S (2004). Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23, 3550–3560.
21. Tsareva SA, Moriggl R, Corvinus FM, Wiederanders B, Schütz A, Kovacic B, and Friedrich K (2007). Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia 9, 279–291.
22. Ossowski L (1992). Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 52, 6754–6760.
23. Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, and Huet G (2005). Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer 103, 1676–1686.
24. Zhu Y, Spitz MR, Lei L, Mills GB, and Wu X (2001). A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61, 7825–7829.
25. Kasper M, Regl G, Eichberger T, Frischauf AM, and Aberger F (2007). Efficient manipulation of Hedgehog/GLI signaling using retroviral expression systems. Methods Mol Biol 397, 67–78.
26. Rutter JL, Mitchell TI, Butticè G, Meyers J, Gusella JF, Ozelius LJ, and Brinckerhoff CE (1998). A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58, 5321–5355.
27. Schütz A, Schneidenbach D, Aust G, Tannapfel A, Steinert M, and Wittekind C (2002). Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumour Biol 23, 179–184.
28. Schütz A, Härtig W, Wobus M, Grosche J, Wittekind Ch, and Aust G (2005). Expression of ADAM15 in lung carcinomas. Virchows Arch 446, 421–429.
29. Remmele W, Hildebrand U, Hienz HA, Klein PJ, Vierbuchen M, Behnken LJ, Heicke B, and Scheidt E (1986). Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol 409, 127–147.
30. Zugowski C, Lieder F, Müller A, Gasch J, Corvinus FM, Moriggl R, and Friedrich K (2011). STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol Chem 392, 449–459.
31. Itoh M, Murata T, Suzuki T, Shindoh M, Nakajima K, Imai K, and Yoshida K (2006). Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25, 1195–1204.
32. Zhao X, Sun X, and Li XL (2012). Expression and clinical significance of STAT3, P-STAT3, and VEGF-C in small cell lung cancer. Asian Pac J Cancer Prev 13, 2873–2877.
33. He B, You L, Xu Z, Mazieres J, Lee AY, and Jablons DM (2004). Activity of the suppressor of cytokine signaling-3 promoter in human non-small-cell lung cancer. Clin Lung Cancer 5, 366–370.
34. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, Paladino D, Zhao J, Chen Y, and Gunning PT, et al (2012). Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 109, 9623–9628.
35. Azijli K and Yuvaraj S (2012). Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells. J Cell Sci 125, 4651–4661.
36. Fernandes A, Hamburger AW, and Gerwin BI (1999). ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int J Cancer 83, 564–570.
37. Kopantzev Y, Heller M, Swaminathan N, and Rudikoff S (2002). IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells. Oncogene 21, 6791–6800.
38. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Céspedes MV, Sevillano M, Nadal C, Jung P, and Zhang XH, et al (2012). Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571–584.
39. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, Jones SA, Rose-John S, and Scheller J (2007). Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110, 1748–1755.
40. Ogata Y, Osaki T, Naka T, Iwahori K, Furukawa M, Nagatomo I, Kijima T, Kumagai T, Yoshida M, and Tachibana I, et al (2006). Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia 8, 817–825.
41. Lin YC, Hung MS, Lin CK, Li JM, Lee KD, Li YC, Chen MF, Chen JK, and Yang CT (2011).CK2 inhibitors enhance the radiosensitivity of human non-small cell lung cancer cells through inhibition of stat3 activation. Cancer Biother Radiopharm 26, 381–388.
42. Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, Soo RA, Christensen JG, Lee JH, and Cho BC (2012). Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 11, 2254–2264.
43. Su WP, Cheng FY, Shieh DB, Yeh CS, and Su WC (2012). PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine 7, 4269–4283.
44. Yan C, Ding X, Wu L, Yu M, Qu P, and Du H (2013). Stat3 downstream gene product chitinase 3-like 1 is a potential biomarker of inflammation-induced lung cancer in multiple mouse lung tumor models and humans. PLoS One 8, e61984.